Harnessing the Power of Collaboration and Training Within Clinical Data Science to Generate Real‐World Evidence in the Era of Precision Oncology

Rivera, Donna R.; Lee, Jerry S.H.; Hsu, Elizabeth R.; Khoury, Muin J.; Meng, Frank; Olivero, Ofelia A.; Penberthy, Lynne; Tourassi, Georgia D.

doi:10.1002/cpt.1459

Cited by 4 publications

(5 citation statements)

References 6 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Critical Nature of Collaboration and Mentorship -the Keys to Success Overall That a workshop of this complexity is distilled to 2 groups of 12 questions and ideas is a remarkable achievement (17)(18)(19). The Supplementary Table S1 (https://doi.org/10.1667/ RADE-22-00012.1.S1) includes the questions and the Supplementary Table S2 (https://doi.org/10.1667/RADE-22-00012.1.S1) lists various tools and skills.…”

Section: Discussionmentioning

confidence: 99%

Predictive Radiation Oncology – A New NCI–DOE Scientific Space and Community

Buchsbaum

Jaffray

et al. 2022

Radiation Research

View full text Add to dashboard Cite

With a widely attended virtual kickoff event on January 29, 2021, the National Cancer Institute (NCI) and the Department of Energy (DOE) launched a series of 4 interactive, interdisciplinary workshops—and a final concluding “World Café” on March 29, 2021—focused on advancing computational approaches for predictive oncology in the clinical and research domains of radiation oncology. These events reflect 3,870 human hours of virtual engagement with representation from 8 DOE national laboratories and the Frederick National Laboratory for Cancer Research (FNL), 4 research institutes, 5 cancer centers, 17 medical schools and teaching hospitals, 5 companies, 5 federal agencies, 3 research centers, and 27 universities. Here we summarize the workshops by first describing the background for the workshops. Participants identified twelve key questions—and collaborative parallel ideas—as the focus of work going forward to advance the field. These were then used to define short-term and longer-term “Blue Sky” goals. In addition, the group determined key success factors for predictive oncology in the context of radiation oncology, if not the future of all of medicine. These are: cross-discipline collaboration, targeted talent development, development of mechanistic mathematical and computational models and tools, and access to high-quality multiscale data that bridges mechanisms to phenotype. The workshop participants reported feeling energized and highly motivated to pursue next steps together to address the unmet needs in radiation oncology specifically and in cancer research generally and that NCI and DOE project goals align at the convergence of radiation therapy and advanced computing.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive Radiation Oncology – A New NCI–DOE Scientific Space and Community

Buchsbaum

Jaffray

et al. 2022

Radiation Research

View full text Add to dashboard Cite

show abstract

“…The present study required an estimation of the number of patients in whom pCR would be achieved given a BC patient population exposed to NAC. As Brazil has a constrained-budget healthcare system, in which innovative drugs are not available in the public system, we searched the National Surgical Adjuvant Breast and Bowel Project Protocols (NSABP) B-27 study results [9] for evidence related to the use of neoadjuvant chemotherapy in Brazil. In that study, of patients who received neoadjuvant chemotherapy, 26.3% of non-pCR group patients died (n = 490 deaths out of 1857 patients), whereas 10.3% of pCR group patients died (n = 42 out of 397 patients) in the eight-year median follow-up.…”

Section: Analysesmentioning

confidence: 99%

“…Regarding Brazilian clinical trial participation data, the 2021 Interfarma [8] report shows participation in only 2.4% of cancer studies worldwide. Given the importance of these issues, real-world data (RWD) are essential to complement information obtained in clinical trials to verify the effectiveness of treatments currently available in a given service or health system [9].…”

mentioning

confidence: 99%

Evaluation of the Pathological Complete Response (pCR) as a Surrogate Endpoint of Neoadjuvant Chemotherapy: Real-World Evidence

Antonini,

Mattar,

Richter

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Neoadjuvant chemotherapy (NAC), which in the past was only used only in for locally advanced disease, is currently being used upfront, especially in to treat aggressive breast cancer (BC). Real-world data (RWD) can address important research questions based on daily routine daily cancer care. The objective of this study was to characterize the pathological complete response (pCR) and its relationship with overall survival (OS) and disease-free survival (DFS) in BC patients with BC who received NAC at a Brazilian public reference center, a. And also to characterize the relationship between pCR and the BC subtypes, of BC and DFS and OS. Methods This was a retrospective cohort study based on a large BC database from a women’s health reference center for women’s health in Brazil. Patients with BC diagnosed between 2011 and 2020 were included if they received NAC. Data on regarding demographics, cancer-related information, treatment-related information, pCR, OS and DFS were collected. Survival analyses were performed using the semiparametric Kaplan‒Meier method to assess OS and DFS by using pCR status, considering BC diagnosis as the index date. Results A total of 1601 patients were included. BC patients were on average 49 years old and presented with stage IIIa disease (35%). Most patients had invasive nonspecial- type (NST) disease (94%);, and 86.7% of patients had a the Ki-67 index was ≥ 14 in 86.7% of patients. The overall pCR rate was 22.7%;, and pCR was observed more frequently in triple-negative and luminal B subtypes. A significant proportion of pCR patients were alive (89% vs. 61%, log-rank p < 0.0001) and had a greater DFS status (90% vs. 66%, log-rank p < 0.0001). Only Luminal A patients did not have a association of better worse OS and DFS associated with pCR. Conclusions Updated real-world data on for BC patients who received NAC in this Brazilian cohort have showedn that a 22.7%the pCR rate was 22.7% for all cancer subtypes and stages. Only Luminal A patients’ pCR status was not didn’t have associatedion of with a better OS and or DFS with pCR.

show abstract

“…However, attention should be paid on education and training, as different stakeholders invested in this rapidly evolving space have varying levels of understanding of RWD and RWE. Rivera et al . discuss the need to embrace collaborative interdisciplinary teams and to enhance clinical data scientist training opportunities (Table of ref.…”

Section: It Takes a Villagementioning

confidence: 99%

“…discuss the need to embrace collaborative interdisciplinary teams and to enhance clinical data scientist training opportunities (Table of ref. ) to generate functionable knowledge that can be translated to actionable evidence.…”

Section: It Takes a Villagementioning

confidence: 99%